MPGN II - Genetically determined by defective complement regulation?

Pediatric Nephrology

Volumn 22, Issue 1, 2007, Pages 2-9

  Licht, Christoph ^a,e   Schlötzer Schrehardt, Ursula ^b   Kirschfink, Michael ^c   Zipfel, Peter F ^d   Hoppe, Bernd ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HANS KNÖLL INSTITUTE   (Germany)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Alternative pathway of the complement system; C3 nephritic factor (C3NeF); Factor H; Factor H autoantibodies; Membranoproliferative glomerulonephritis type II (MPGN II)

Indexed keywords

ACETYLSALICYLIC ACID; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRITIC FACTOR; PREDNISONE; PROTEIN ANTIBODY; RECOMBINANT PROTEIN;

DISEASE COURSE; EDITORIAL; GENE MUTATION; GLOMERULUS BASEMENT MEMBRANE; HEREDITY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 2; NONHUMAN; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEINURIA;

ANIMALS; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT FACTOR H; DISEASE PROGRESSION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY; MUTATION;

EID: 33846452493     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0299-8     Document Type: Editorial

References (42)

1. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 16:1392-1403
2. Schaerer K (2002) Membranoproliferative glomerulonephritis. In: Schärer K, Mehls O (eds) Pädiatrische Nephrologie. Springer, Berlin Heidelberg New York, pp 230-232
3. Zipfel PF, Heinen S, Jozsi M, Skerka C (2006) Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 43:97-106
4. Jackson EC, McAdams AJ, Strife CF, Forristal J, Welch TR, West CD (1987) Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation. Am J Kidney Dis 9:115-120
5. Johnson RJ, Alpers CE, Schena FP (2003) Membranoproliferative glomerulonephritis and cryoglobulinemic glomerulonephritis. In: Johnson RJ, Feehally J (eds) Comprehensive clinical nephrology. Mosby, Edinburgh, pp 25.1-25.10
6. International Study of Kidney Diseases in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephritic syndrome from initial response to prednisone. J Pediatr 98:561-564
7. Ault BH (2000) Factor H and the pathogenesis of renal disease. Pediatr Nephrol 14:1045-1053
8. Schwertz R, de Jong R, Gretz N, Kirschfink M, Anders D, Schärer K; Arbeitsgemeinschaft Pädiatrische Nephrologie (1996) Outcome of idiopathic membranoproliferative glomerulonephritis in children. Acta Paediatr 85:308-312
9. Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M (1995) Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95:1054-1061
10. Jansen JH, Hogasen K, Grondahl AM (1995) Porcine membranoproliferative glomerulonephritis type II: An autosomal recessive deficiency of factor H. Vet Rec 137:240-244
11. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M (2002) Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31:424-428
12. Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116:1-7
13. West CD (1994) Nephritic factors predispose to chronic glomerulonephritis. Am J Kidney Dis 24:956-963
14. West CD, McAdams AJ (1999) The alternative pathway C3 convertase and glomerular deposits. Pediatr Nephrol 13:448-453
15. Thurman JM, Holers VM (2006) The central role of the alternative complement pathway in human disease. J Immunol 176:1305-1310
16. Walport MJ (2001) Complement (first of two parts). N Engl J Med 344:1058-1066
17. Walport MJ (2001) Complement (second of two parts). N Engl J Med 344:1140-1144
18. Zipfel PF (2001) Complement factor H: Physiology and pathophysiology. Semin Thromb Hemost 27:191-199
19. Fearon DT (1978) Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971-1975
20. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK (2000) Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol 164:4742-4751
21. Zipfel PF, Smith RJH, Heinen S (2005) The role of complement in membranoproliferative glomerulonephritis. In: Zipfel PF (ed) Complement and kidney diseases. Birkhäuser, Basel, pp 199-221
22. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, Remuzzi G, Noris M (2001) The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 12:297-307
23. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B (2005) Successful plasma therapy for atypical hemolytic uremic syndrome (aHUS) caused by factor H deficiency due to a mutation in the complement cofactor protein (CCP) domain 15. Am J Kidney Dis 45:415-421
24. Schwertz R, Rother U, Anders D, Gretz N, Schärer K, Kirschfink M (2001) Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long-term follow-up. Pediatr Allergy Immunol 12:166-172
25. Daha MR, Van Es LA (1981) Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor. Immunology 43:33-38
26. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein b1H. Proc Natl Acad Sci USA 73:3268-3272
27. Józsi M, Manuelian T, Heinen S, Oppermann M, Zipfel PF (2004) Attachment of the soluble complement regulator factor H to the cell and tissue surfaces: Relevance for pathology. Histol Histopathol 19:251-258
28. Ault BH, Schmidt BZ, Fowler NL, Kashtan CE, Ahmed AE, Vogt BA, Colten HR (1997) Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 272:25168-25175
29. Cunningham PN, Quigg RJ (2005) Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 16:1214-1222
30. Hegasy GA, Manuelian T, Hogasen K, Jansen JH, Zipfel PF (2002) The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II. Am J Pathol 161:2027-2034
31. Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF (2006) Deletion of Lys224 in the regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease. Kidney Int 70:42-50
32. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S (1999) Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 163:4590-4596
33. Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ (1992) Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175:939-950
34. Lindshaw MA, Stapleton FB, Cuppage FE, Forristal J, West CD, Schreiber RD, Wilson CB (1987) Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. Am J Nephrol 7:470-477
35. Marder HK, Coleman TH, Forristal J, Beischel L, West CD (1983) An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis. Kidney Int 23:749-758
36. Jelezarova E, Lutz HU (2005) IgG naturally occurring antibodies stabilize and promote the generation of the alternative complement pathway C3 convertase. Mol Immunol 42:1393-1403
37. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A (2004) Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 19:3160-3164
38. Levin A (1999) Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int 55:S41-S46
39. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438-446
40. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19:1716-1723
41. Alexander JJ, Pickering MC, Haas M, Osawe I, Quigg RJ (2005) Complement factor H limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 16:52-57
42. Kurtz KA, Schlueter AJ (2002) Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apheresis 17:135-137